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Biomarker development is a major focus of research in cancer as well as in other
diseases. We seek biomarkers for many purposes, including risk assessment, screening,
diagnosis and prognosis. New molecular technologies in particular promise to provide
biomarkers that can inform about risk and help guide clinical decisions.

There are two basic statistical approaches for evaluating such biomarkers. The first
models the risk of disease (or disease outcome) as a function of the biomarker(s) using,
for example, logistic (or Cox) regression. The value of a marker is measured by its effect
on risk. The second summarizes marker performance with classification performance
measures such as sensitivity and specificity, predictive values and ROC curves. There is
controversy about which approach is most appropriate. Moons and Harrell (1) argue in
favor of risk models since ultimately the patient wants to know his risk given his
biomarker measurement. On the other hand, Pepe et al. (2) emphasize that the public
health value of a marker lies in the fraction of diseased subjects detected, i.e., sensitivity,
and the fraction of non-diseased subjects falsely identified as diseased, i.e., 1-specificity.

Both statistical approaches are frequently applied, often to the same data. However, the
relationship between them is unclear. Of particular concern, the two approaches
frequently yield apparently contradictory results. A marker that is strongly related to risk
is often a poorly performing classifier. A marker that is a strong predictor of risk after
controlling for other risk factors often adds little to them in terms of improving
classification performance.
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In this commentary, we present a new graphic, the Predictiveness Curve. It is useful for
assessing the value of a risk model when applied to the population. We also extend the
plot to simultaneously evaluate the risks associated with a marker and the marker’s
performance as a classifier. This integrated approach provides a more complete and
comprehensive analysis than current practice.

Data for Illustration

We illustrate with data from the Prostate Cancer Prevention Trial (PCPT) recently
reported in this journal (3). 5519 men on the placebo arm of the study underwent prostate
biopsy and had at least 2 PSA measurements in the 3 years prior to biopsy. Along with
PSA and PSA change over time, data on family history of prostate cancer, results of
digital rectal exam (DRE), age, ethnicity and prior biopsy were used to model the risk of
finding prostate cancer and the risk of high grade disease (Gleason ≥ 7) at the time of
prostate biopsy. Since the data are used only for illustrating a statistical method, in the
interests of being relatively brief we restrict the analysis to high grade disease, although
a similar approach could be used for all prostate cancer. Of the 5519 men, 4.7%
ultimately were found to have high grade disease. Table 1 shows the results of the logistic
regression analysis. For the diagnosis of high grade disease, PSA, DRE, age and prior
negative biopsy appeared to be predictive of risk.

The Predictiveness Curve
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We can calculate an individual’s risk given data on his risk factors using the fitted risk
model. For the prostate cancer example,the calculation (3) is

risk of high grade disease = exp(Y ) /{1 + exp(Y )}
where

Y = −5.94 + 1.30 log PSA + 0.03age + 0.99(DRE positive) − 0.37(prior biopsy)

This risk calculator of Thompson et al (3) is available online at
http://www.compass.fhcrc.org/edrnnci/bin/calculator/main.asp . We calculated the risk
for each of the individuals in the PCPT study. The Predictiveness Curve in Figure 1
shows the distribution of risks. To create the curve we ordered the risks from lowest to
highest and plotted their values. We see that at 90% on the x-axis the risk value is 0.104.
This indicates that 90% of subjects in the cohort have risks below 0.104 and only 10%
have risks above 0.104.

Another way of using the graph is to start at a risk value on the y-axis and to read the
corresponding percent on the x-axis. For example, at risk = 0.20 we see that the percent is
97.8%. That is, 2.2% of subjects in the cohort have risks above 0.20. At risk =0.02 the
percent is 39.0%, indicating that 39.0% of subjects in the cohort have risks below 0.02.
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What does the graph offer that is not summarized in Table 1? It shows the range and
distribution of risk levels associated with the model when it is applied to the population
from which the cohort was drawn. Consider that an individual wants to use his calculated
risk in deciding whether or not to have a biopsy. The decision is more straightforward if
his risk of disease is close to 0 or 1. If his calculated risk is in an equivocal range, it is not
helpful. Suppose, for illustration, that 20% risk of high grade disease is sufficiently high
to recommend a biopsy and that 2% risk is sufficiently low to decide against biopsy.
Individuals whose risks are calculated in the range (0.02,0.20) are unsure about whether
or not they should have a biopsy obtained. (A formal cost-benefit analysis that
incorporates their risk of disease might be helpful, although specifying costs and benefits
is always difficult.) A risk model will be most useful for individual decision making if
calculated risks of having high-grade disease tend to exceed 20% or be less than 2%. We
see from Figure 1 however that the prostate cancer risk model leaves the majority of men,
58.8%, in the indecisive risk region. Alternative thresholds might be chosen for defining
high and low risk. If it is reasonable to assume that a man with a <5% risk of high grade
disease may defer further evaluation while a man with a >10% risk would prefer an
evaluation, the corresponding indecisive risk region would contain only 25% of the
population. It is important to keep in mind however, that individuals typically do not
distinguish between minor variations in risk so we prefer to use the more extreme
definitions of low and high risk in our illustrations.

http://biostats.bepress.com/uwbiostat/paper289

Different risk models can be compared through their Predictiveness Curves. In figure 2
we see that the Predictiveness Curve for PSA alone is almost identical to that of the more
comprehensive model that includes the additional risk factors of age, prior biopsy, family
history and DRE. Both models calculate risks less than the 0.02 low risk threshold for
36% and 39% of the population, respectively. At the high risk end of the scale, the PSA
model puts 1.2% of subjects above the 0.20 risk level while the more comprehensive
model puts 2.2% of subjects in the high risk range. For comparison we also include a
simulated marker with much better performance. The simulated marker (SIM) identifies
68.1% of subjects as low risk, 6.0% as high risk and leaves 25.9% with calculated risks in
the equivocal (0.02,0.20) range. This marker was simulated as a standard normal random
variable for controls and a normal (mean = 2 , standard deviation = 1) random variable
for cases.

Another approach to comparing risk models is with the R-squared statistic generalized
from linear to logistic regression (4). The values 0.053, 0.066 and 0.310 for PSA alone,
for PSA and other factors and for SIM, respectively, corroborate the results depicted in
the Predictiveness curves. However the interpretation of the R-squared value as the
proportion of the variance in disease explained by the model is not very intuitive. We
have recently provided a more understandable interpretation as the difference in the
average risks between diseased and non-diseased subjects (5). Interestingly, R2 can be
calculated as a summary index from the Predictiveness Curve

1

R = ³ (Pred (v) − ρ ) 2 dv / ρ (1 − ρ )
2

0
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where ȡ = disease prevalence in the study population and Pred(v) is the value of the risk
at the vth percentile. The denominator term in R2 is a standardization factor leading to
values in the range 0 (useless prediction) to 1 (perfect prediction). We find the display of
the Predictiveness curve more useful than simply reporting its R2 summary index.

In our plots we include a horizontal line located at the risk level equal to the prevalence.
This corresponds to the Predictiveness Curve for a completely uninformative risk model,
one that assigns all subjects equal risk. It serves as a reference curve. Moreover,
mathematically the positive area above the horizontal line but below the Predictiveness
Curve must equal the negative area below the horizontal line but above the Predictiveness
curve. Better markers will show larger positive and negative areas and we find the
horizontal line a helpful visual aid.

Classification Based on Risk

Clinical decision criteria are often of the form “marker ≥ threshold.” For example, the
criterion “PSA ≥ 4.0 ng/ml” has been used to recommend biopsy. However, decision
criteria might be better formulated in terms of risk. For example, the criterion “risk ≥
0.20” could be used to recommend biopsy. Criteria formulated in terms of risk are natural
and intuitive. In addition, they are statistically optimal in the sense that they minimize
false positive and false negative error rates, a notion defined precisely in (6).
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The performance of decision rules based on a risk model can be calculated from the
model’s Predictivness Curve. We illustrate in Figure 3. For example, the positive
predictive value of the criterion “risk > threshold” is the proportion of the dark
area in the shaded rectangle that lies under the curve. The true positive fraction
corresponding to this criterion is the same dark area under the curve divided by the
prevalence of disease. Although exact calculations will be made directly from the data,
approximate calculations can be made by simply viewing the Predictiveness Curve.

An Integrated Approach

The plot shown in Figure 4a is a comprehensive summary of the population performance
of the risk model based on SIM, the simulated marker. It allows one to assess decision
criteria from multiple points of view. For example, we see that by recommending biopsy
for subjects with risks above 0.20, 6% of the population proceed to biopsy, 57% of
subjects with high-grade disease are detected, while 3.4% of subjects without high-grade
disease are unnecessarily biopsied. The choice of threshold might be dictated by
controlling one or more of the performance measures. Maintaining the false positive
fraction (1-specificity) at a low level is paramount in primary screening, while a high true
positive fraction (sensitivity) is often crucial in diagnostic settings. Yet the corresponding
risk threshold will also be an important aspect to consider in order to ensure that
decisions are satisfying to individuals. To illustrate, in Figure 4b, if we choose the
positivity criterion on the basis of a true positive fraction (TPF) =0.95 say, the
corresponding risk threshold is 0.013. Sending individuals for biopsy when their risks are
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as low as 0.013 may be inappropriate. In addition we see that the corresponding false
positive fraction is unacceptably high, FPF=37%.

DISCUSSION

The fitting of risk models to biomarker and risk factor data is a valuable exercise.
However, the usefulness of the model as applied to the population is rarely evaluated. We
suggest for this purpose the Predictiveness Curve, a display of the risk distribution
revealed by the biomarkers and risk factors in the population. A desirable model performs
a triage process, placing most individuals at high or low risk values, where decisions are
more easily made. In developing a biomarker, we need to define reasonable thresholds
for high and low risk, thresholds that depend on the clinical context. The Predictiveness
Curve then shows the capacity of the marker to identify meaningful variations in risk. By
simultaneously displaying predictiveness and classification performance with the
Integrated plot, we believe that biomarker researchers are better equipped to understand
the potential utility of a risk model applied in the population. This practical goal
motivated our research.

One must always be cautious to interpret a risk model and its Predictiveness Curve in the
context of the population that gave rise to the data. Strictly speaking the ‘population'
refers to a population for which the available cohort is representative subsample. As
noted by Thompson et al (3), PCPT participants may not reflect the general U.S.
population. Subjects in the PCPT study were participants in a clinical trial. They may
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differ from the general population because of eligibility criteria, characteristics related to
their self-selection for the study and their care during the course of the study. Therefore
their risk model may not apply with complete fidelity to the general population. We use
the data here simply to illustrate statistical methodology and for that purpose it serves
well. Nevertheless it raises questions about risk assessment using research cohorts in
general, and clinical trial cohorts in particular. Although they may provide a useful
starting point for marker evaluation and marker comparison, ultimately risk models
should be calculated on cohorts representative of the population.

The analyses we applied to the PCPT data showed that additional risk factors do not add
substantially to the predictiveness of PSA alone, in that the fraction of subjects in the
equivocal risk range is not appreciably decreased. A risk factor can have a large effect on
risk, but if it is rare in the population, it cannot substantially influence population risk
prediction. In the PCPT, few subjects have risk factor levels that substantially change
their risk calculated on the basis of PSA alone. For only 72 subjects did their risk change
from <0.2 to >0.2 and, not surprisingly, a positive DRE accounted for most of these
(92%). Nevertheless, the fact that the risk model has limitations on a population level
does not mean that it won’t contribute in a meaningful way to the biopsy decision-making
process of some individuals, which was the specified purpose of developing the risk
model (3).

The predictiveness curve is easy to calculate once a risk model has been fitted. We have
developed procedures for constructing confidence intervals and for comparing points on
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two curves under cross-sectional cohort designs (5). Bootstrap techniques can also be
applied. For case-control study designs it is possible to estimate risk from a fitted logistic
regression if the disease prevalence is known. Corresponding procedures to estimate the
predictiveness curve from case-control data are currently under development. For settings
with an outcome variable that is a time to an event, such as disease or death, one can
define risk as a function of time, i.e., the probability of an event in a time interval (0,t).
Predictiveness curves would be plotted for different time intervals.

Using the same dataset to fit a risk model and to assess its performance can lead to
optimistic estimates of model performance. This is an issue particularly when many
predictors are involved. Cross-validation or bootstrapping can be applied in these settings
to correct for this bias. In our analysis of the PCPT data, the model that included other
risk factors in addition to PSA showed minimal improvement over PSA alone with
uncorrected Predictiveness Curves, so correcting for bias was unnecessary.

We note that fitting an adequate risk model is an ambitious statistical task, more
ambitious than estimating an ROC curve, for example. The former is akin to estimating a
probability density while the latter is akin to estimating a cumulative distribution
function. Therefore, with small datasets where risk modeling is not feasible one might
proceed to simply evaluating the usual classification performance measures such as the
ROC curve. With larger datasets, classification performance measures should also be
assessed but perhaps in conjunction with the predictiveness curve in order to integrate the
risk modeling and classification approaches to data analysis.
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Captions.

Table 1. Logistic regression analysis of risk for high grade disease as reported in
Thompson et al (3).

Figure 1. Predictiveness curve for the risk model shown in Table 1 that includes PSA,

age, prior biopsy, family history and DRE as risk factors for high grade prostate cancer.
Figure 2. Predictiveness Curves for PSA alone, PSA and other factors and the simulated

(SIM) marker.
Figure 3. Schematic diagram showing how classifier performance parameters relate to

the Predictiveness Curve. Positive Predictive Value=dark/shade dark + intermediate;
Negative Predictive Value = white area/white + light shade; True Positive Fraction = dark
shade/dashed box; False Positive Fraction=intermediate shade/1-dashed box.
Figure 4. The integrated predictiveness and classification plot for the simulated marker

using two criteria for defining a positive biomarker result. Criterion (a) is risk >0.20.
Criterion (b) is TPF=0.95.
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Table 1

Factor
logPSA
Age (years)
DRE
Prior biopsy
Constant

Log Odds Ratio
1.30
0.03
0.99
–0.37
–5.94

P-value
<0.001
0.02
<0.001
0.04
—
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